# Oncimmune Holdings plc Senior Leadership Team Appointments and Board Change

- Link: https://www.directorstalkinterviews.com/oncimmune-holdings-plc-senior-leadership-team-appointments-and-board-change/412762619
- Published: 2018-12-07T07:26:58+00:00
- Author: Giles Arbor

**Oncimmune Holdings plc** (LON: ONC), a leader in the development, manufacture 
and commercialisation of personalised immunodiagnostics for the screening, detection
and care of cancer, has announced the appointment to the Senior Leadership Team 
of Matthew Hall as Group Chief Financial Officer and Andrew Stewart as General Counsel
and Company Secretary.

Andrew Millet has stepped down from the Board as Chief Financial Officer, Director
and Company Secretary. Andrew will be available to the Company for the next six 
months to ensure an orderly transition of his CFO responsibilities.

Matthew Hall is a seasoned finance professional with over 25 years’ of corporate
finance experience in a number of leading organisations and fast-growing companies.
Most recently he was Chief Financial Officer at Tusk Therapeutics and Simbec-Orion
Group. Previously, Matthew was Chief Financial Officer at Sphere Medical Holding
plc where he was appointed to lead the company’s successful IPO and prior to that
was Chief Financial Officer of IS Pharma plc, where he was closely involved in the
merger of IS Pharma plc and Sinclair Pharma plc. Matthew is a Chartered Accountant
with a degree in Economics.

Andrew Stewart is an international business lawyer with extensive healthcare industry
experience. Andrew’s previous role was at Smith & Nephew plc, where he was responsible
for leading the legal teams supporting the group’s global M&A efforts and European
commercial operations. Before that, he was Chief Counsel, Global Transactions and
Corporate at Shire plc. Before joining industry, Andrew spent a number of years 
in private legal practice, primarily at Clifford Chance. Andrew has extensive experience
advising FTSE100 companies and multinationals and has held executive leadership 
positions. He holds degrees in Law and Science (Biochemistry and Immunology).

> **Dr Adam Hill, CEO of Oncimmune Holdings plc commented: **
> “The additions to the Senior Leadership Team we are announcing today will help
> me drive the delivery of Oncimmune’s strategy to capitalise on the wide range 
> of opportunities presented by our proprietary autoantibody-based platform. Matthew
> and Andrew both have highly relevant experience and will support the Board in 
> its day-to-day activities as we set about delivering the next chapter of our Company’s
> strategy over the next three years.
> “I would like to thank Andrew Millet for his 15 years of service to Oncimmune.
> Andrew has been instrumental in supporting Oncimmune’s journey to date, helping
> the Company through a step change in process and reporting after Oncimmune’s IPO
> in May 2016. We wish him well for the future as he seeks to spend more time on
> his portfolio of directorships and outside interests.”

Share on:
